Larimar Therapeutics, Inc.
LRMR · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $185 | $138 | $247 |
| - Cash | $90 | $21 | $21 | $33 |
| + Debt | $3 | $5 | $5 | $5 |
| Enterprise Value | – | $169 | $121 | $219 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$48 | -$28 | -$31 | -$31 |
| % Margin | – | – | – | – |
| Net Income | -$48 | -$26 | -$29 | -$29 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.61 | -0.41 | -0.46 | -0.45 |
| % Growth | -48.8% | 10.9% | -2.2% | – |
| Operating Cash Flow | -$29 | -$19 | -$27 | -$22 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$29 | -$19 | -$27 | -$22 |